MONTGOMERY, Texas--(BUSINESS WIRE)--March 7, 2006--Endovasc, Inc (OTCBB: EVSC) a Business Development Company focused on acquiring and investing in innovative drug development in the areas of cardiovascular and metabolic medicine, is pleased to announce that Robert B. Rutherford M.D., FACS, FRCS has accepted Endovasc’s invitation to act as Scientific Advisor for the Phase III studies on Liprostin. Dr. Rutherford is a leading expert in the field of vascular surgery and medicine and has been working with Endovasc since the fall of 2005, providing guidance for the Company’s upcoming Phase IIIa trials of Liprostin.
